EN DE
Watch Exagen Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Exagen Inc (XGN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Exagen Inc stock $5.34, price $5.26, upside +1.5%, quality 34 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EI Exagen Inc logo Thin data Nov 10, 2026

Exagen Inc

XGN · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Revenue last quarter +16% vs. a year ago.
Fair value $5.34 · Fairly valued
Mixed Growth (revenue 5y +9.7 %/yr in USD)
Moderate debt
Insiders sold $418,624 (6M)
Quality 34/100
Loss-making · -26.6% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 12/100
Thin data
Estimate
Watch Exagen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.44 $1.36 Fair Value $5.34 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.36 – $14.44 · fair‑value band $4.01 – $6.68 · the $5.26 price screens below the $5.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Exagen in your weekly email

Every Wednesday you see whether Exagen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.

Show moreShow less

The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test.

Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019.

Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Stock analysis

Exagen Inc (XGN) currently trades at $5.26, while our estimate is $5.34, so the stock looks roughly fairly valued today (gap 1.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.01 (bear) to $6.68 (bull), the price of $5.26 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Exagen Inc reported revenue of $66.6M in FY2025 versus $48.3M in FY2021, a compound +8.4%/yr. Reported net income was −$20.0M in FY2025.

Key figures

Market cap $184M Micro · P/S ratio 2.59 · EPS (TTM) $−0.7200 · Net margin −26.6% · Return on equity −114% · Return on assets (EBIT) −33.6% (5-year average) · Operating margin −8.6% · Revenue (TTM) $71.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 2%, XGN screens cheaper than that median.

Fair Value

Bear $4.01 Fair Value $5.34 Bull $6.68
Price $5.26 · Upside +1.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 46
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $418,624 and none bought.

  • BuyJorey Chernett10% owner2× since Oct 19, 2026: 29,585 shares, avg. $6.61$195,682Nov 10, 2026
  • SaleJorey Chernett10% owner11,265 shares at $6.14$69,167Nov 6, 2026
  • SaleJohn AballiPresident and CEO, Director3× since Feb 24, 2026: 61,422 shares, avg. $5.99$367,880Oct 16, 2026
  • SaleJeffrey G. BlackChief Financial Officer2× since Feb 24, 2026: 22,198 shares, avg. $6.96$154,551Sep 1, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
Start year 2020 (pandemic). Over 10 years: +14.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−36.2% (2020) → −21.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch XGN, get fair value alerts →

Compare Exagen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside +1.5% · Above median
Profitability
Return on assets −34.4% · Bottom 25%
Net margin (12 months) −26.6% · Bottom 25%
Operating margin (12 months) −8.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 15.9% · Above median
Balance sheet
Debt / equity 1.28× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 10.55× · Priciest 25%
P/S (12 months) 2.59× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)35 · sector 12
FUTURE (revenue growth)80 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)36 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs XGN
Illumina, Inc ILMN $214.91 $234.44 +9% vs XGN
IQVIA Holdings IQV $275.15 $299.58 +9% vs XGN
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs XGN
Danaher Corporation DHR $236.11 $209.18 −11% vs XGN
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs XGN
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs XGN
Agilent Technologies, Inc A $177.88 $64.53 −64% vs XGN
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs XGN
Waters Corporation WAT $475.52 $91.26 −81% vs XGN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Exagen Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Exagen Inc Fair Value". https://www.fairvalue-calculator.com/stock/XGN

Frequently asked questions

Is Exagen Inc (XGN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $5.34 versus a price of $5.26, about +2% upside (fairly valued).
What is the fair value of XGN?
Our estimate for Exagen Inc is $5.34 (as of Nov 10, 2026), built from audited fundamentals. The current price: $5.26.
What is the quality score of XGN?
Exagen Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Exagen Inc (XGN)?
Our calculated price target is the estimate of $5.34 (as of Nov 10, 2026). Cautious scenario $4.01, optimistic scenario $6.68. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Exagen Inc stock forecast for 2026?
Our estimate puts fair value at $5.34, about +2% upside versus a price of $5.26 (fairly valued). Cautious scenario $4.01, optimistic scenario $6.68. The calculation is refreshed regularly with new filings.
What is the revenue of Exagen Inc (XGN)?
Exagen Inc reported trailing-twelve-month revenue of about $71.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Exagen Inc (XGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Exagen Inc it is $5.34 per share (as of Nov 10, 2026), against a price of $5.26.
Is Exagen Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, XGN trades below its calculated fair value: price $5.26, fair value $5.34, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XGN?
No. The price is what the market pays today ($5.26); the fair value is what the company's own numbers justify ($5.34). For Exagen Inc the two are $0.0800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Exagen Inc worth?
The market values Exagen Inc at about $184M (market capitalisation, as of Nov 10, 2026). Per share that is $5.26; our models calculate a fair value of $5.34 per share.
What do the bullish and bearish scenarios say about XGN?
Our models span a range for Exagen Inc: cautious scenario $4.01, base $5.34, optimistic $6.68 per share (as of Nov 10, 2026, price $5.26). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Exagen Inc (XGN)?
Balance-sheet figures for Exagen Inc (as of Nov 10, 2026): return on equity −113.8%, debt of 1.28 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is XGN from its 52-week high?
Exagen Inc trades at $5.26, about 45% below its 52-week high of $9.59 and 98% above the low of $2.65 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.34 is for.
Which stocks are comparable to Exagen Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Exagen Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $5.26, calculated fair value $5.34 (+2%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Exagen Inc currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Exagen Inc (XGN)?
The closing price on Nov 10, 2026 was $5.26. Our estimate is $5.34, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Exagen Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Exagen Inc

How large is the market capitalisation of Exagen Inc (XGN)?
The market capitalisation of Exagen Inc is $184M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Exagen Inc (XGN)?
The price-to-sales ratio of Exagen Inc is 2.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Exagen Inc (XGN)?
Earnings per share at Exagen Inc are $−0.7200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Exagen Inc (XGN)?
The net margin of Exagen Inc is −26.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Exagen Inc (XGN)?
The return on equity (ROE) of Exagen Inc is −114% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Exagen Inc (XGN)?
On an EBIT basis the return on assets of Exagen Inc is −33.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Exagen Inc (XGN)?
The operating margin of Exagen Inc is −8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Exagen Inc (XGN)?
Revenue at Exagen Inc is growing +15.9% versus a year earlier (3y avg +13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Exagen Inc (XGN) generate?
The free cash flow of Exagen Inc is −$14.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Exagen Inc (XGN) hold?
Exagen Inc holds more cash than debt, $6.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Exagen Inc in the live analysis

One click puts Exagen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.